IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Williams et al. Serial No.: 10/662,757 Filed: September 15, 2003 Confirmation No.: 1920 Group Art Unit: 1715

PATENT

eptember 15, 2003 Examiner: Lin, James
INTRALUMINAL PROSTHESES AND CARBON DIOXIDE-ASSISTED METHODS OF

IMPREGNATING SAME WITH PHARMACOLOGICAL AGENTS

Date: October 7, 2010

Mail Stop Amendment Commissioner for Patents Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT COVER LETTER

Sir:
Attached is an Information Disclosure Statement listing of documents, together with a copy of
any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or
U.S. patent application publication is not provided herewith in accordance with 37 C.F.R. § 1.98(a)(2)(ii).
☐ In accordance with 37 CFR 1.97(b) , the information disclosure statement is being filed:
\square (1) within three months of the filing date of a national application other than a continued
prosecution application under §1.53(d);
\square (2) within three months of the date of entry of the national stage as set forth in §1.491 in
an international application;
(3) before the mailing of a first Office Action on the merits; or
\square (4) before the mailing of a first Office Action after the filing of a request for continued
examination under §1.114.
☑ In accordance with 37 CFR 1.97(c), the information disclosure statement is being filed after
the period specified in 37 CFR 1.97(b) above, but before the mailing date of any of a final action under
§1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the
application, and is accompanied by <u>one</u> of the following:
(1) The statement specified under 37 CFR 1.97(e) , as follows:
☐ Each item of information contained in the information disclosure statement
was first cited in any communication from a foreign patent office in a counterpart foreign
application not more than three months prior to the filing of the information disclosure
statement; <u>or</u>
☐ No item of information contained in the information disclosure statement was
cited in a communication from a foreign patent office in a counterpart foreign application,
and, to the knowledge of the person signing the certification after making reasonable
inquiry, no item of information contained in the information disclosure statement was
known to any individual designated in §1.56(c) more than three months prior to the filing
of the information disclosure statement; <u>or</u>
(2) The fee set forth in §1.17(p);
☐ In accordance with 37 CFR 1.97(d) , the information disclosure statement is being filed after
the period specified in 37 CFR 1.97(c) above, but on or before payment of the issue fee, and is
accompanied by both of the following:

Filing Date: September 15, 2003 Page 2 of 2 (1) The statement specified under **37 CFR 1.97(e)**, as follows: ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement; and \square (2) The fee set forth in §1.17(p); In accordance with 37 CFR 1.97(g), the information disclosure statement shall not be construed as a representation that a search has been made. In accordance with 37 CFR 1.97(h), the information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56(b). The Director is hereby authorized to charge the fee specified in 37 C.F.R. § 1.17(p), and any fee deficiency or credit any overpayment, to Deposit Account No. 50-0220; or No fee is believed due. However, the Director is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220. Respectfully submitted, Bodk I Needham J. Boddie, II Registration No. 40,519 Attorney for Applicant **Customer Number 20792** Myers Bigel Sibley & Sajovec, P.A. P.O. Box 37428, Raleigh, NC 27627 919-854-1400 919-854-1401 (Fax) CERTIFICATION OF TRANSMISSION I hereby certify that this correspondence is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4) to the U.S. Patent and Trademark Office on October 7, 2010.

In re: Williams et al. Application No.: 10/662,757

Name: Anthony DeRosa